Geron GERN
Geron FY 2021: revenue $1.4M, up 451%; diluted EPS −$0.35
- Form
- 10-K
- Filed
- Period
- Importance
- Notable
- Accession
- 0001564590-22-009627
- Document
- 10-K
- Exhibit 4.1
- Description of capital stock
- Exhibit 10.20
- Mar 2022 amended non-employee directors' comp policy
- Exhibit 10.22
- Amended and restated severance plan
Key figures from this report
These are the numbers Geron reported for the year ended Dec 31, 2021, as tagged in the filing’s XBRL data, each against the year before. A plain-English reading of this report is not written yet.
- Revenue$1.4M+451% from $253K in FY 202010-K income statement, on EDGAR
- Net income−$116.1MAgainst −$75.6M in FY 202010-K income statement, on EDGAR
- Diluted EPS−$0.35Against −$0.28 in FY 202010-K income statement, on EDGAR
- Cash and cash equivalents$34.9M+251% from $9.9M in FY 2020Cash and equivalents only; the company page adds short-term investments.10-K balance sheet, on EDGAR
- Cash from operations−$95.6MAgainst −$66.7M in FY 202010-K cash flow statement, on EDGAR
Similar companies
Companies of similar size in SIC 2834 and related industry codes: the same peer list as the financial tables.
- Intellia Therapeutics NTLA public float $869M, Jun 30, 2025
- Wave Life Sciences WVE public float $851M, Jun 30, 2025
- CorMedix CRMD public float $910M, Jun 30, 2025
- Niagen Bioscience NAGE public float $814M, Jun 30, 2025
- Nurix Therapeutics NRIX public float $808M, May 30, 2025